The global antifungal drugs market is expected to reach USD 13.03 Billion by 2026, according to a new report by Reports and Data. Antifungal drugs are used to treat fungal infections. Rising prevalence of fungal infections and fungal diseases is one of the most significant factors anticipated to boost the market demand in the upcoming years. Though most of the infections caused by fungus are non-fatal in nature but cause great inconvenience in the people suffering from it and as a result would require proper medication for their cure.

An increase in the level of disposable income of the people coupled with increasing awareness towards healthy well-being is likely to boost the growth of the market in the future. An increase in the population of people with weak immunity who are vulnerable to fungal infection and an increase in the elderly population are also forecasted to drive the market in the future.

Additionally, increased investments made in RD along with public-private partnership agreements in the pharmaceutical industry to come up with novel and more effective drug for treating fungal infections as well as the increasing demand for OTC (over-the-counter) antifungal drugs especially for treatment for skin related infection is causative of the growth of the market.

Top Companies Profiled in the Report Include:

Merck Co. Inc., Novartis AG, Pfizer Inc., Bayer AG, Enzon Pharmaceuticals Inc., GlaxoSmithKline PLC, Abbott, Sigma-Aldrich, Glenmark Pharmaceuticals, and Astellas Pharma Inc. among others.

Market Overview:

The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop medications to cater to the growing unmet clinical demand on a global level. Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past. In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities. Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.  

The report offers a comprehensive overview of the regional bifurcation of the market with respect to market share, market size, revenue growth, import/export, production and consumption patterns, macro and micro economic growth factors, regulatory framework, investment and funding opportunities, and presence of key players in each region including North America, Asia Pacific, Latin America, Europe, and Middle East Africa. The report offers a country-wise analysis to further discuss the revenue growth and lucrative growth opportunities for the Antifungal Drugs market in these key regions.

Country-wise regional analysis covers:

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • BENELUX
  • Italy
  • Spain
  • Switzerland
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Rest of LATAM
• Middle East Africa
  • Saudi Arabia
  • U.A.E.
  • South Africa
  • Turkey
  • Rest of MEA

Additionally, the report consists a detailed analysis of the segmentation of the Antifungal Drugs market based on product types and end-use/application offered in the Antifungal Drugs market.

Drug Class Outlook (Revenue, USD Million; 2016-2026)

• Azoles
  • Voriconazole (Vfend)
  • Posaconazole (Noxafil)
  • Clotrimazole (Canesten)
  • Isavuconazole (CRESEMBA)
  • Others
• Echinacandins
  • Caspofungin (Cancidas)
  • Micafungin (Mycamine/ Funguard)
  • Others
• Polyenes
  • Amphotericin (AmBisome)
  • Others
• Allylamines
  • Terbinafine (Lamisil)
  • Others
• Others

Dosage Form Outlook (Revenue, USD Million; 2016-2026)

• Liquid or Spray
• Shampoo
• Gels
• Injections
• Pills
• Creams

Indication Outlook (Revenue, USD Million; 2016-2026)

• Candidiasis
• Dermatophytosis
• Aspergillosis
• Others

Distribution Channel Outlook (Revenue, USD Million; 2016-2026)

• Hospitals Pharmacies
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.